XENEXenon Pharmaceuticals Inc.
What is the market doing?
No clear lean: nothing decisive, though insiders net buying.
Rangebound, no clear trend. Price is −29% vs its 200-day average.
Insiders were net buyers over the 90 days ending Oct 8, 2026.
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How XENE is trading
Xenon Pharmaceuticals Inc. is −1.4% over the past year while the S&P 500 is +18%: 20 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −29%
vs 200-day average · a clear downtrend
- RSI (14)
- 38
RSI (14) · neutral
- Below its 52-week high
- 47%
Below its 52-week high
Details›
- Last close2026-10-09
- $36.44
- 1 monthS&P 500 +2.7%
- −38%
- 1 yearS&P 500 +18%
- −1.4%
- 5 yearsS&P 500 +88%
- +107%
- vs 50-day average$53.75
- −32%
- 52-week high
- $68.91
- 52-week low
- $36.17
- Annualised volatility
- 58%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $1.0M
| Year | Return |
|---|---|
| 2026 (year to date) | −19% |
| 2025 | +14% |
| 2024 | −15% |
| 2023 | +17% |
| 2022 | +26% |
| 2021 | +103% |
| 2020 | +17% |
| 2019 | +108% |
| 2018 | +123% |
| 2017 | −63% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +3.8% |
| Feb | 10 | 7 of 10 | +7.2% |
| Mar | 10 | 3 of 10 | −3.1% |
| Apr | 10 | 5 of 10 | +4.1% |
| May | 10 | 3 of 10 | −4.5% |
| Jun | 10 | 6 of 10 | +7.1% |
| Jul | 11 | 5 of 11 | +3.7% |
| Aug | 11 | 8 of 11 | +7.7% |
| Sep | 11 | 2 of 11 | −7.9% |
| Oct | 11 | 5 of 11 | +5.5% |
| Nov | 10 | 7 of 10 | +4.1% |
| Dec | 10 | 7 of 10 | +7.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.